Home > > > > > Report Detail

Exocrine Pancreatic Insufficiency - Pipeline Insight, 2020

Publisher Name :
Date: 16-Jan-2020
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

Exocrine Pancreatic Insufficiency Overview

"Exocrine Pancreatic Insufficiency Pipeline Insight, 2020" Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Exocrine Pancreatic Insufficiency Market. A Detailed Picture Of The Exocrine Pancreatic Insufficiency Pipeline Landscape Is Provided, Which Includes The Disease Overview And Exocrine Pancreatic Insufficiency Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Exocrine Pancreatic Insufficiency Commercial Assessment And Clinical Assessment Of The Exocrine Pancreatic Insufficiency Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Exocrine Pancreatic Insufficiency Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Exocrine Pancreatic Insufficiency Of Pipeline Development Activities

The Report Provides Insights Into:

- All Of The Companies That Are Developing Therapies For The Treatment Of Exocrine Pancreatic Insufficiency With Aggregate Therapies Developed By Each Company For The Same.

- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Exocrine Pancreatic Insufficiency Treatment.

- Exocrine Pancreatic Insufficiency Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Exocrine Pancreatic Insufficiency Market.

- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Exocrine Pancreatic Insufficiency Analytical Perspective By DelveInsight

- In-Depth Exocrine Pancreatic Insufficiency Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

- Exocrine Pancreatic Insufficiency Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

Scope Of The Report

- The Exocrine Pancreatic Insufficiency Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Exocrine Pancreatic Insufficiency Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

- It Comprises Of Detailed Profiles Of Exocrine Pancreatic Insufficiency Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

- Detailed Exocrine Pancreatic Insufficiency Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Exocrine Pancreatic Insufficiency.

Report Highlights

- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Exocrine Pancreatic Insufficiency.

- In The Coming Years, The Exocrine Pancreatic Insufficiency Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Exocrine Pancreatic Insufficiency R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Exocrine Pancreatic Insufficiency Treatment Market. Several Potential Therapies For Exocrine Pancreatic Insufficiency Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Exocrine Pancreatic Insufficiency Market Size In The Coming Years.

- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Exocrine Pancreatic Insufficiency ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

Key Questions

- What Are The Current Options For Exocrine Pancreatic Insufficiency Treatment?

- How Many Companies Are Developing Therapies For The Treatment Of Exocrine Pancreatic Insufficiency?

- What Are The Principal Therapies Developed By These Companies In The Industry?

- How Many Therapies Are Developed By Each Company For The Treatment Of Exocrine Pancreatic Insufficiency?

- How Many Exocrine Pancreatic Insufficiency Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Exocrine Pancreatic Insufficiency?

- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Exocrine Pancreatic Insufficiency Market?

- Which Are The Dormant And Discontinued Products And The Reasons For The Same?

- What Is The Unmet Need For Current Therapies For The Treatment Of Exocrine Pancreatic Insufficiency?

- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Exocrine Pancreatic Insufficiency Therapies?

- What Are The Clinical Studies Going On For Exocrine Pancreatic Insufficiency And Their Status?

- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

- What Are The Key Designations That Have Been Granted For The Emerging Therapies For Exocrine Pancreatic Insufficiency?

- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Exocrine Pancreatic Insufficiency?

Exocrine Pancreatic Insufficiency - Pipeline Insight, 2020

Table of Contents

1. Report Introduction
2. Exocrine Pancreatic Insufficiency
2.1. Overview
2.2. History
2.3. Exocrine Pancreatic Insufficiency Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Exocrine Pancreatic Insufficiency Diagnosis
2.6.1. Diagnostic Guidelines
3. Exocrine Pancreatic Insufficiency Current Treatment Patterns
3.1. Exocrine Pancreatic Insufficiency Treatment Guidelines
4. Exocrine Pancreatic Insufficiency - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Exocrine Pancreatic Insufficiency companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Exocrine Pancreatic Insufficiency Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Exocrine Pancreatic Insufficiency Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Exocrine Pancreatic Insufficiency Late Stage Products (Phase-III)
7. Exocrine Pancreatic Insufficiency Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Exocrine Pancreatic Insufficiency Discontinued Products
13. Exocrine Pancreatic Insufficiency Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Exocrine Pancreatic Insufficiency Key Companies
15. Exocrine Pancreatic Insufficiency Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Exocrine Pancreatic Insufficiency Unmet Needs
18. Exocrine Pancreatic Insufficiency Future Perspectives
19. Exocrine Pancreatic Insufficiency Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

List of Tables

Table 1: Exocrine Pancreatic Insufficiency Diagnostic Guidelines
Table 2: Exocrine Pancreatic Insufficiency Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Exocrine Pancreatic Insufficiency Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Exocrine Pancreatic Insufficiency Late Stage Products (Phase-III)
Table 18: Exocrine Pancreatic Insufficiency Mid Stage Products (Phase-II)
Table 19: Exocrine Pancreatic Insufficiency Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products

List of Figures

Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Exocrine Pancreatic Insufficiency companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Exocrine Pancreatic Insufficiency Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
  • Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period. The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
  • Global Lansoprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 102
    The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period. The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
  • Global Esomeprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 89
    The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Irritable Bowel Syndrome (IBS) market: According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
  • Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Diarrhea Drug market: According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
  • Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
  • Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 136
    Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
  • Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Pentasa (Ulcerative Colitis) market: According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs